173 related articles for article (PubMed ID: 32975694)
1. Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone.
Poujade L; Samaran Q; Mura F; Guillot B; Meunier I; Du-Thanh A
Doc Ophthalmol; 2021 Apr; 142(2):257-263. PubMed ID: 32975694
[TBL] [Abstract][Full Text] [Related]
2. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated retinopathy treated with ipilimumab therapy.
Audemard A; de Raucourt S; Miocque S; Comoz F; Giraud JM; Dreno B; Bienvenu B; Rogerie MJ; Dompmartin A
Dermatology; 2013; 227(2):146-9. PubMed ID: 24051549
[TBL] [Abstract][Full Text] [Related]
4. Electroretinographic Findings in Melanoma-Associated Retinopathy Treated by Intravitreal Dexamethasone Implant.
Abou-Samra A; Tzekov R; Yannuzzi NA; Tarabishy AB
Ophthalmic Surg Lasers Imaging Retina; 2021 Aug; 52(8):454-456. PubMed ID: 34410186
[TBL] [Abstract][Full Text] [Related]
5. TRIPLE THERAPY WITH RITUXIMAB, INTRAVENOUS IMMUNOGLOBULIN, AND INTRAVITREAL CORTICOSTEROIDS FOR MELANOMA-ASSOCIATED RETINOPATHY: TTRIIC DOES THE TRICK.
Hamdan SA; Breazzano MP; Daniels AB
Retin Cases Brief Rep; 2022 Nov; 16(6):775-778. PubMed ID: 33165302
[TBL] [Abstract][Full Text] [Related]
6. Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma.
Khaddour K; Khanna S; Ansstas M; Jakhar I; Dahiya S; Council L; Ansstas G
Cancer Immunol Immunother; 2021 Sep; 70(9):2497-2502. PubMed ID: 33544215
[TBL] [Abstract][Full Text] [Related]
7. Delayed presentation of melanoma-associated retinopathy and subsequent resolution with cytoreduction surgery.
Stead RE; Fox MA; Staples E; Lim CS
Doc Ophthalmol; 2013 Oct; 127(2):165-71. PubMed ID: 23794161
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
Dalal MD; Morgans CW; Duvoisin RM; Gamboa EA; Jeffrey BG; Garg SJ; Chan CC; Sen HN
Ophthalmology; 2013 Dec; 120(12):2560-2564. PubMed ID: 24053997
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings.
Jacobzone C; Cochard-Marianowski C; Kupfer I; Bettembourg S; Dordain Y; Misery L; Cochener B; Sassolas B
Arch Dermatol; 2004 Oct; 140(10):1258-61. PubMed ID: 15492190
[TBL] [Abstract][Full Text] [Related]
10. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo.
Lei B; Bush RA; Milam AH; Sieving PA
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):262-6. PubMed ID: 10634629
[TBL] [Abstract][Full Text] [Related]
11. Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature.
Casselman P; Jacob J; Schauwvlieghe PP
J Ophthalmic Inflamm Infect; 2023 Apr; 13(1):16. PubMed ID: 37022562
[TBL] [Abstract][Full Text] [Related]
12. ACUTE EXUDATIVE PARANEOPLASTIC POLYMORPHOUS VITELLIFORM MACULOPATHY DURING VEMURAFENIB AND PEMBROLIZUMAB TREATMENT FOR METASTATIC MELANOMA.
Sandhu HS; Kolomeyer AM; Lau MK; Shields CL; Schuchter LM; Nichols CW; Aleman TS
Retin Cases Brief Rep; 2019 Spring; 13(2):103-107. PubMed ID: 28614138
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy.
Potter MJ; Thirkill CE; Dam OM; Lee AS; Milam AH
Ophthalmology; 1999 Nov; 106(11):2121-5. PubMed ID: 10571347
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-associated retinopathy.
Elsheikh S; Gurney SP; Burdon MA
Clin Exp Dermatol; 2020 Mar; 45(2):147-152. PubMed ID: 31742740
[TBL] [Abstract][Full Text] [Related]
15. Severe course of cutaneous melanoma associated paraneoplastic retinopathy.
Kellner U; Bornfeld N; Foerster MH
Br J Ophthalmol; 1995 Aug; 79(8):746-52. PubMed ID: 7547786
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.
Hung WC; Cheng HC; Wang AG
Doc Ophthalmol; 2022 Dec; 145(3):263-270. PubMed ID: 36173494
[TBL] [Abstract][Full Text] [Related]
17. Localized retinal manifestations of paraneoplastic autoimmune retinopathy.
Eadie JA; Ip MS; Ver Hoeve JN
Retin Cases Brief Rep; 2014; 8(4):318-21. PubMed ID: 25372537
[TBL] [Abstract][Full Text] [Related]
18. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma.
Pföhler C; Haus A; Palmowski A; Ugurel S; Ruprecht KW; Thirkill CE; Tilgen W; Reinhold U
Br J Dermatol; 2003 Jul; 149(1):74-8. PubMed ID: 12890197
[TBL] [Abstract][Full Text] [Related]
20. Lesson of the month 1: Seeing snowflakes.
Patel A; Aslam A; Orr G; Perkins W
Clin Med (Lond); 2015 Aug; 15(4):394-5. PubMed ID: 26407395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
